Study Reveals Political Statements Directly Influenced Medical Decisions
New research published in The Lancet has demonstrated how former President Donald Trump's promotion of unproven medical claims about autism directly influenced patient care and prescribing patterns across the United States. The study examined the period following a White House briefing where Trump advised pregnant women against taking Tylenol while promoting an old generic drug as a treatment for autism.
Significant Shifts in Medication Patterns
Researchers discovered that for nearly three months after the presidential briefing, Tylenol orders for pregnant women aged 15 to 44 in emergency departments dropped by 10% compared to projected trends. Simultaneously, outpatient prescriptions of the generic drug leucovorin for children aged 5 to 17 surged by 71% above expected levels during the same study period from late September to early December.
"It just shows that in our country right now, health care has been politicized in a way that political messages are driving and impacting care — and not always for good," said Dr. Susan Sirota, a pediatrician from Highland Park, Illinois, who was not involved with the research. The study found no similar shifts in comparable medications, suggesting these changes were directly tied to the presidential briefing rather than broader medical trends.
Medical Community Expresses Concern
These shifts occurred despite strong criticism from medical organizations who emphasized that Tylenol remains safe during pregnancy and that leucovorin should not be broadly used for autism treatment. The American Academy of Pediatrics does not recommend routine use of leucovorin for autistic children, noting that evidence remains limited despite some early, small-scale studies suggesting potential benefits in carefully selected cases.
Dr. Michael Barnett, co-author of the study from Brown University School of Public Health, noted that "it reflected how an unconventional news conference by a political leader could change not just patient behavior but prescribing as well." He contrasted this approach with past administrations where "there are lots of layers of approval and expert consensus" before officials make significant announcements about medical topics.
Understanding the Medical Context
Pregnant women typically use Tylenol (also known by generic names acetaminophen and paracetamol) for pain or fever management. Untreated fevers during pregnancy, particularly in the first trimester, increase risks for miscarriages, preterm birth, and other complications according to the Society for Maternal-Fetal Medicine. While some studies have raised questions about potential associations between Tylenol use during pregnancy and autism risk, many others have found no connection.
Leucovorin, a derivative of folic acid, is primarily used to reduce toxic side effects of certain chemotherapy drugs and treat rare blood disorders. It has been studied for neurological conditions including cerebral folate deficiency and for subsets of autistic children, but evidence supporting its use for autism remains limited. In late January, the European Journal of Pediatrics retracted a study evaluating leucovorin as an autism treatment.
Real-World Impact on Clinical Practice
Dr. Sirota reported that after the federal announcement about leucovorin, families in her practice began asking about obtaining the drug for their autistic children. She educated them about the limited evidence, discussed potential side effects including irritability, nausea, vomiting, and skin issues like dermatitis, and ultimately did not prescribe it.
"It feels like a pattern with our government, right? They keep building on these houses of cards that just fall down," Sirota said. "This politicizing of medicine just in general, and moving away from science, has been so challenging."
Study Limitations and Broader Implications
The research had limitations, including that it did not capture all Tylenol use by pregnant women since most people purchase the painkiller over the counter outside hospital settings. However, the findings clearly demonstrate how political messaging can directly influence medical decision-making at both patient and provider levels.
The study period examined changes in drug ordering and prescribing compared to projected trends, revealing how political announcements can create immediate shifts in healthcare practices despite medical consensus to the contrary. This research adds to growing concerns about the politicization of healthcare and the potential consequences when political figures make medical claims without scientific consensus.
